Dovitinib: all 57 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsTerminatedNCT05571969Phase 1Results posted
- Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)TerminatedNCT01994590Phase 2Results posted
- Maintenance Dovitinib for Colorectal and Pancreas CancerTerminatedNCT01888965Phase 2Results posted
- Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
- Dovitinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT01753713Phase 2Results posted
- Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expressionTerminatedNCT01732107Phase 2Results posted
- Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal CancerCompletedNCT01676714Phase 2Results posted
- Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast CancerTerminatedNCT01528345Phase 2Results posted
- Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaCompletedNCT01524692Phase 2Results posted
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerTerminatedNCT01484041Phase 1/2Results posted
- Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to ImatinibCompletedNCT01478373Phase 2Results posted
- Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258CompletedNCT01440959Phase 2Results posted
- A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial CancerCompletedNCT01379534Phase 2Results posted
- TKI 258 in Von Hippel-Lindau Syndrome (VHL)TerminatedNCT01266070Phase 2Results posted
- TKI258 for Metastatic Inflammatory Breast Cancer PatientsCompletedNCT01262027Phase 2Results posted
- A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line TreatmentCompletedNCT01232296Phase 2Results posted
- Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT01223027Phase 3Results posted
- TKI258 in Castrate Resistant Prostate CancerCompletedNCT00831792Phase 2Results posted
- Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric CancerTerminatedNCT02720926Phase 1
- Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal TumorsWithdrawnNCT02268435Phase 1
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
- A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADTWithdrawnNCT02065323Phase 2
- Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic CancerWithdrawnNCT02048943Phase 1
- Dovitinib (TKI258) in the Treatment of Patients With Relapsed GlioblastomaStatus unknownNCT01972750Phase 1
- An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid CancerCompletedNCT01964144Phase 2
- Dovitinib Plus Docetaxel in Gastric CancerCompletedNCT01921673Phase 1/2
- Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung CancerStatus unknownNCT01861197Phase 2
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCCStatus unknownNCT01791387Phase 2
- A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate ChemotherapyTerminatedNCT01769547Phase 2
- Dovitinib(TKI258) in Patients With Castration-resistant Prostate CancerCompletedNCT01741116Phase 2
- Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1CompletedNCT01719549Phase 2
- Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal CancerCompletedNCT01714765Phase 1
- Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.CompletedNCT01700270Phase 1
- Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
- A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT01678105Phase 2
- Dovitinib in Neuroendocrine TumorsCompletedNCT01635907Phase 2
- Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsCompletedNCT01596647Phase 1
- A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma PatientsCompletedNCT01576380Phase 2
- Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid TumorsTerminatedNCT01548924Phase 1
- Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01515969Phase 1
- Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaCompletedNCT01514526Phase 2
- Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary CancersCompletedNCT01497392Phase 1
- Phase I Dose Escalating Study of TKI258CompletedNCT01471548Phase 1
- Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic FunctionCompletedNCT01443481Phase 1
- Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid TumorsCompletedNCT01421004Phase 1
- Dovitinib in Adenoid Cystic CarcinomaCompletedNCT01417143Phase 2
- Safety of CHIR-258 (TKI258) in Advanced Solid TumorsTerminatedNCT01270906Phase 1
- Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid TumorsCompletedNCT01155713Phase 1
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal TranslocationCompletedNCT01058434Phase 2
- Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid TumorsCompletedNCT01030055Phase 1
- Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast CancerCompletedNCT00958971Phase 2
- Phase II Study of TKI258 in Advanced Urothelial CarcinomaCompletedNCT00790426Phase 2
- A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell CancerCompletedNCT00715182Phase 1
- Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid MalignanciesCompletedNCT00669097Phase 1
- Safety of TKI258 in Advanced/Metastatic Melanoma SubjectsCompletedNCT00303251Phase 1/2
- Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid LeukemiaTerminatedNCT00279773Phase 1
- TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaTerminatedNCT00243763Phase 1